Professor, Department of Medicine Director, Center for Research and Clinical Care in Liver Disease Jacobs School of Medicine and Biomedical Sciences
University at Buffalo

Andrew H. Talal, MD, MPH
Professor, Department of Medicine
Director, Center for Research and Clinical Care in Liver Disease
Jacobs School of Medicine and Biomedical Sciences
University at Buffalo
Buffalo, New York

Andrew Talal, MD, MPH is a physician-scientist with more than 20 years’ experience in hepatitis C virus (HCV), especially in disenfranchised populations, such as substance users. He is currently Professor of Medicine at Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, where he has developed a translational liver research center and biorepository with funding from the Kaleida Health Foundation. Further, he is the principal investigatory on a 5-year award from the Patient Centered Outcomes Research Institute to study telemedicine-based HCV treatment among patients on opiate agonist therapy. The study consists of 12 telemedicine sites across New York State conducting integrated treatment of HCV and opioid use disorder. Dr. Talal also conducts numerous industry-sponsored clinical drug trials that operate within the Liver Center. As a researcher he has published over 115 papers on topics such as HCV, telemedicine, drug metabolism and the social determinants of health. His research also led to the development of liver fine needle aspiration as a diagnostic technique for liver sampling. Dr. Talal was recently appointed by New York State Governor Cuomo to a task force to advise the state on its HCV Elimination Plan based upon Dr. Talal’s expertise on HCV and his use of emerging technologies to reach and to treat patients who otherwise would not have access to these services.

Presentation(s):